OClawVPS.com
Edit

Columbus Venture Partners

https://www.columbusvp.com/
Last activity: 07.11.2025
Active
Portfolio
3
Mentions
41
Employees: 11-50
Email

Portfolio 3

DateNameWebsiteTotal RaisedLocation
07.11.2025Accipiter ...accipiterbio.com$12.7MUnited Sta...
03.05.2023ARTHEx Bio...arthexbiotech.com$138.32MSpain
30.03.2022Integra Th...integra-tx.com$25.7MSpain

Mentions in press and media 41

DateTitleDescription
08.11.2025Accipiter Biosciences Secures $12.7M Seed Funding, Revolutionizing Protein TherapiesAccipiter Biosciences, a Seattle biotech, exited stealth with $12.7 million in seed funding. The company pioneers de novo multifunctional protein therapeutics. Its computational platform designs novel biologics from scratch. These single mo...
07.11.2025Accipiter Biosciences: $12.7 Million Seed Funding Closed To Develop De Novo Protein TherapiesAccipiter Biosciences has emerged from stealth with $12.7 million in seed funding to advance a new class of de novo multifunctional protein therapeutics designed to treat complex diseases. The seed round was co-led by Takeda and Flying Fish...
07.11.2025Accipiter Biosciences Raises $12.7M in Seed FinancingAccipiter Biosciences, a Seattle, WA-based biotechnology company developing de novo multifunctional biologics to treat complex diseases, raised $12.7M in Seed funding. The round was co-led by Takeda and Flying Fish Partners, with participat...
26.09.2025Nscale raises $1.1BN Series B, the biggest European energy deals in H1 2025, and inside Antler’s "Day Zero" strategyThis week, we tracked more than 80 tech funding deals worth over €2.2 billion, and over 10 exits, M&A transactions, rumours, and related news stories across Europe. In addition to this week's top financials, we've also indexed the most ...
22.09.2025ARTHEx Biotech: Series B Round Upsized To $87 Million For Myotonic Dystrophy Treatment DevelopmentARTHEx Biotech, a biotechnology company in the clinical stage of development, has recently made a significant announcement regarding its financing efforts. The company focuses on creating targeted RNA medicines, particularly for rare geneti...
16.09.2025Spanish cancer startup Highlight Therapeutics closes €15 million round to further skin tumour treatmentValencia’s Highlight Therapeutics, a biopharmaceutical company focused on the development of next-generation immunotherapies, has raised €15 million aimed at strengthening their position in the treatment of skin tumours and accelerating its...
08.09.2025Integra Therapeutics raises €10.7M to advance FiCAT platform and CAR-T validationBarcelona-based Integra Therapeutics has closed a €10.7 million pre-Series A round to advance its gene writing technologies designed to improve the safety, precision, and efficacy of advanced therapies. Founded in 2020 by Dr. Marc Güell and...
08.09.2025Integra Therapeutics Raises €10.7M in FundingIntegra Therapeutics, a Barcelona, Spain-based gene writing tools provider, raised €10.7M in funding. Backers included IC Fund (European Commission) and CDTI Innvierte (Government of Spain) and current investors (AdBio, Columbus, Invivo and...
03.02.2025Quibim: Imaging Biomarker Company Raises $50 Million (Series A)Quibim, a leading health technology company pioneering imaging biomarkers for precision medicine, announced the closing of its $50 million Series A funding round. And the company has experienced remarkable growth in the number of patients a...
29.01.2025Quibim's Leap into the U.S. Market: A $50M Investment in Precision MedicineIn the world of health technology, precision is paramount. Quibim, a Valencia-based healthtech company, has just secured a significant $50 million in Series A financing. This funding is not just a number; it’s a lifeline aimed at transformi...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In